Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Newcastle disease + H9 avian influenza + infectious bursal disease trivalent inactivated vaccine (Youbang Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Youbang Pharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a trivalent inactivated veterinary vaccine developed by **Youbang Pharmaceutical** (Uni-Bio) for the immunization of poultry, specifically chickens. The vaccine provides simultaneous protection against three major avian pathogens: **Newcastle disease virus (NDV)**, **H9 subtype avian influenza virus (AIV)**, and **infectious bursal disease virus (IBDV)**, also known as Gumboro disease. Formulated as an oil emulsion, it contains killed viral antigens that elicit a robust antibody-mediated immune response. This product is part of Youbang Pharmaceutical's commercial portfolio and is approved for use in preventing significant economic losses in the poultry industry caused by these respiratory and immunosuppressive diseases.
- Other names
- 鸡新城疫、禽流感(H9亚型)、传染性法氏囊病三联灭活疫苗Newcastle disease + H9 AI + IBD trivalent inactivated vaccineNDV+H9 AI+IBDV trivalent inactivated vaccine
Beyond the preview
Go deeper on Newcastle disease + H9 avian influenza + infectious bursal disease trivalent inactivated vaccine (Youbang Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newcastle disease + H9 avian influenza + infectious bursal disease trivalent inactivated vaccine (Youbang Pharmaceutical).